Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters

BACKGROUND: CD40 signalling can synergise with chemotherapy in preclinical cancer models, and early clinical studies are promising. We set out to define the immunological changes associated with this therapeutic combination to identify biomarkers for a response to the therapy. Here, we present seria...

Descripción completa

Detalles Bibliográficos
Autores principales: McDonnell, Alison M., Cook, Alistair, Robinson, Bruce W. S., Lake, Richard A., Nowak, Anna K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472884/
https://www.ncbi.nlm.nih.gov/pubmed/28619093
http://dx.doi.org/10.1186/s12885-017-3403-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472884/
https://www.ncbi.nlm.nih.gov/pubmed/28619093
http://dx.doi.org/10.1186/s12885-017-3403-5

Ejemplares similares